Literature DB >> 3436097

Evidence for activation of complement in patients with AIDS related complex (ARC) and/or lymphoadenopathy syndrome (LAS).

R Perricone1, L Fontana, C de Carolis, C Carini, M C Sirianni, F Aiuti.   

Abstract

The complement system was examined in 16 patients with AIDS-related complex (ARC) (n = 5) and/or lymphoadenopathy syndrome (LAS) (n = 11). Of these patients 62.5% showed an impairment of classical and/or alternative pathway activity associated with the presence of cleavage fragments of C3 and/or B and a significant reduction of many complement factors. The data indicate pathological complement activation in these patients through the classical and/or alternative pathway. Complement activation was more severe in patients with ARC than in those with LAS, and greater in drug abusers than homosexuals. The lack of efficient complement in the patients can be considered an 'acquired complement deficiency' with possible importance in the failure to combat the HIV attack.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3436097      PMCID: PMC1542193     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  35 in total

1.  Mechanism of complement activation by radiographic contrast media.

Authors:  C M Arroyave; E M Tan
Journal:  Clin Exp Immunol       Date:  1977-07       Impact factor: 4.330

2.  Activation of the alternative complement pathway by human B cell lymphoma lines is associated with Epstein-Barr virus transformation of the cells.

Authors:  I McConnell; G Klein; T F Lint; P J Lachmann
Journal:  Eur J Immunol       Date:  1978-07       Impact factor: 5.532

3.  Inhibition of the classical and alternative pathways by amino acids and their derivatives.

Authors:  Y Takada; Y Arimoto; H Mineda; A Takada
Journal:  Immunology       Date:  1978-03       Impact factor: 7.397

4.  Haemolytic diffusion plate assays for factors B and D of the alternative pathway of complement activation.

Authors:  A Martin; P J Lachmann; L Halbwachs; M J Hobart
Journal:  Immunochemistry       Date:  1976-04

5.  Activation of the alternative complement pathway by enveloped viruses containing limited amounts of sialic acid.

Authors:  J J McSharry; R J Pickering; L A Caliguiri
Journal:  Virology       Date:  1981-10-30       Impact factor: 3.616

6.  Serum suppression of lymphocyte activation in vitro in acquired immunodeficiency disease.

Authors:  S Cunningham-Rundles; M A Michelis; H Masur
Journal:  J Clin Immunol       Date:  1983-04       Impact factor: 8.317

7.  Antibody-independent activation of the alternative complement pathway by measles virus-infected cells.

Authors:  J G Sissons; M B Oldstone; R D Schreiber
Journal:  Proc Natl Acad Sci U S A       Date:  1980-01       Impact factor: 11.205

8.  Detection of complement activation by counterimmunoelectrophoresis (CIE).

Authors:  C M Arroyave; E M Tan
Journal:  J Immunol Methods       Date:  1976       Impact factor: 2.303

9.  Abnormalities of B-cell activation and immunoregulation in patients with the acquired immunodeficiency syndrome.

Authors:  H C Lane; H Masur; L C Edgar; G Whalen; A H Rook; A S Fauci
Journal:  N Engl J Med       Date:  1983-08-25       Impact factor: 91.245

10.  Human seminal plasma inhibition of complement.

Authors:  B H Petersen; C J Lammel; D P Stites; G F Brooks
Journal:  J Lab Clin Med       Date:  1980-10
View more
  15 in total

1.  Complement, complement activation and anaphylatoxins in human ovarian follicular fluid.

Authors:  R Perricone; C de Carolis; C Moretti; E Santuari; G de Sanctis; L Fontana
Journal:  Clin Exp Immunol       Date:  1990-11       Impact factor: 4.330

2.  Erythrocyte antibodies in AIDS are associated with mycobacteriosis and hypergammaglobulinemia.

Authors:  J R Bogner; B Gathof; B Heinrich; A Matuschke; U Bäcker; F D Goebel
Journal:  Klin Wochenschr       Date:  1990-11-09

Review 3.  Role of complement and Fc receptors in the pathogenesis of HIV-1 infection.

Authors:  D C Montefiori
Journal:  Springer Semin Immunopathol       Date:  1997

4.  Immunoglobulin and complement complexes in blood following infection with human immunodeficiency virus type 1.

Authors:  X X Peng; M A Wainberg; Y Tao; B G Brenner
Journal:  Clin Diagn Lab Immunol       Date:  1996-01

5.  Self antigen prognostic for human immunodeficiency virus disease progression.

Authors:  C L Bristow; H Patel; R R Arnold
Journal:  Clin Diagn Lab Immunol       Date:  2001-09

6.  Functionally active complement is present in human ovarian follicular fluid and can be activated by seminal plasma.

Authors:  R Perricone; N Pasetto; C De Carolis; E Vaquero; E Piccione; L Baschieri; L Fontana
Journal:  Clin Exp Immunol       Date:  1992-07       Impact factor: 4.330

7.  Effects of Well-Controlled HIV Infection on Complement Activation and Function.

Authors:  Alexandria E-B Rossheim; Tina D Cunningham; Pamela S Hair; Tushar Shah; Kenji M Cunnion; Stephanie B Troy
Journal:  J Acquir Immune Defic Syndr       Date:  2016-09-01       Impact factor: 3.731

8.  Human immunodeficiency virus (HIV)-infected cells and free virus directly activate the classical complement pathway in rabbit, mouse and guinea-pig sera; activation results in virus neutralization by virolysis.

Authors:  G T Spear; B L Sullivan; D M Takefman; A L Landay; T F Lint
Journal:  Immunology       Date:  1991-08       Impact factor: 7.397

9.  CD4-independent binding of HIV-1 to the B lymphocyte receptor CR2 (CD21) in the presence of complement and antibody.

Authors:  D C Montefiori; J Zhou; D I Shaff
Journal:  Clin Exp Immunol       Date:  1992-12       Impact factor: 4.330

10.  Complement activation by human monoclonal antibodies to human immunodeficiency virus.

Authors:  G T Spear; D M Takefman; B L Sullivan; A L Landay; S Zolla-Pazner
Journal:  J Virol       Date:  1993-01       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.